je.st
news
Tag: nausea
LG Develops AI to Combat Virtual Reality Nausea
2018-05-30 16:09:17| Extremetech
LG thinks it has a way to reduce the nausea many experience when gaming in VR, thanks to the use of AI to slash photon latency and frame times. The post LG Develops AI to Combat Virtual Reality Nausea appeared first on ExtremeTech.
Tags: virtual
reality
combat
develops
Survey: Developers prefer Vive to Oculus, but worry about nausea, high price of VR gear
2016-08-25 18:00:18| Extremetech
The results of a new VR survey are in, and show the platforms and projects pulling the most developer attention. There's huge support for VR, but HTC's Vive is the early winner, ahead of the Oculus Rift.
FDA Approves Mercks Single-Dose EMEND (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC)
2016-02-04 14:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. First and Only Intravenous NK1 Receptor Antagonist Approved in the U.S. for Use in MEC KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for single-dose EMEND (fosaprepitant dimeglumine) for injection, Mercks substance P/neurokinin-1 (NK1) receptor antagonist, in combination with other antiemetic medicines, for the prevention of delayed nausea and vomiting in adults receiving initial and repeat courses of moderately emetogenic chemotherapy (MEC). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: combination
agents
receiving
adults
Chemotherapy-induced nausea and vomiting: You may not need to suffer
2015-10-25 18:51:01| Biotech - Topix.net
When Mary Van Dyke was first diagnosed with ovarian cancer, she didn't know that four to five days after her chemotherapy treatment, she would experience nausea and vomiting that caused her to miss out on what she enjoys most -- going to ballgames and attending church with her family.
Tags: to
suffer
nausea
vomiting
Merck Announces Phase 3 Study of Single-Dose EMEND (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
2015-06-29 14:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 3 study investigating the safety and efficacy of single-dose EMEND (fosaprepitant dimeglumine) for Injection, Mercks substance P/neurokinin (NK-1) receptor antagonist, in combination with other anti-vomiting medicines, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in adult cancer patients receiving moderately emetogenic (vomit-inducing) chemotherapy (MEC). Language: English Contact: MerckMedia:Doris Li, 908-740-1903orAn Phan, 908-255-6325orInvestor:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more